Premium
Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis
Author(s) -
Blauvelt A.,
Reich K.,
Warren R.B.,
Szepietowski J.C.,
Sigurgeirsson B.,
Tyring S. K.,
Messina I.,
Bhosekar V.,
Oliver J.,
Papavassilis C.,
Frueh J.,
Langley R.G.B.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15656
Subject(s) - medicine , secukinumab , plaque psoriasis , psoriasis , dosing , clinical trial , maintenance therapy , dermatology , surgery , chemotherapy , psoriatic arthritis
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom